STOCK TITAN

CFO at SOPHiA GENETICS (SOPH) sells 4,933 shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported small open-market sales of 4,933 Ordinary Shares to cover taxes on recent equity vesting. On April 6, he sold 2,520 shares at a weighted average price of $4.8456, followed by 2,413 shares on April 7 at a weighted average price of $4.8771. According to the disclosure, these trades were made under a pre-established Rule 10b5-1 trading plan and were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. After these transactions, he continues to hold 292,861 Ordinary Shares directly, indicating the sales represent a small, routine portion of his overall stake.

Positive

  • None.

Negative

  • None.
Insider CARDOZA GEORGE
Role Chief Financial Officer
Sold 4,933 shs ($24K)
Type Security Shares Price Value
Sale Ordinary Shares 2,413 $4.8771 $12K
Sale Ordinary Shares 2,520 $4.8456 $12K
Holdings After Transaction: Ordinary Shares — 292,861 shares (Direct)
Footnotes (1)
  1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.66 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.70 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold on 2026-04-06 2,520 shares at $4.8456 Open-market sale of Ordinary Shares
Shares sold on 2026-04-07 2,413 shares at $4.8771 Open-market sale of Ordinary Shares
Total shares sold 4,933 shares Net shares sold across both transactions
Shares owned after transactions 292,861 Ordinary Shares Direct holdings following April 7, 2026 sale
Rule 10b5-1 trading plan financial
"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CARDOZA GEORGE

(Last)(First)(Middle)
C/O SOPHIA GENETICS INC.
401 PARK DRIVE, FLOOR 5

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/06/2026S2,520(1)D$4.8456(2)295,274D
Ordinary Shares04/07/2026S2,413(1)D$4.8771(3)292,861D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.66 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.70 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) CFO George Cardoza report in this Form 4?

He reported two small open-market sales totaling 4,933 Ordinary Shares. The filing explains these trades were executed to cover tax withholding obligations from recent restricted stock unit vesting, under a pre-established Rule 10b5-1 trading plan.

How many SOPHiA GENETICS (SOPH) shares did the CFO sell and at what prices?

He sold 2,520 Ordinary Shares at a weighted average price of $4.8456 and 2,413 shares at a weighted average price of $4.8771. Both transactions were reported as open-market sales to satisfy tax withholding obligations.

Why did SOPHiA GENETICS (SOPH) CFO’s Form 4 sales occur on April 6 and 7, 2026?

The sales on April 6 and 7, 2026, were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. This timing links the transactions directly to the equity award vesting events.

Were the SOPHiA GENETICS (SOPH) CFO’s share sales discretionary trades?

The filing states the sales were made under a pre-established Rule 10b5-1 trading plan and "do not represent discretionary trades." This indicates the transactions were pre-planned rather than timed based on market conditions or personal choice.

How many SOPHiA GENETICS (SOPH) shares does the CFO hold after these transactions?

After the April 7, 2026 transaction, the CFO directly holds 292,861 Ordinary Shares. This shows the 4,933 shares sold for tax withholding represent a relatively small portion of his remaining ownership position in the company.

What does ‘weighted average price’ mean in the SOPHiA GENETICS (SOPH) Form 4?

The reported prices are weighted averages because the shares were sold in multiple trades within price ranges, such as $4.66 to $4.95. The insider offers to provide detailed trade-by-trade pricing information to interested parties upon written request.